Market closedNon-fractional
Relay Therapeutics/RLAY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Ticker
RLAY
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
309
Website
www.relaytx.com
RLAY Metrics
BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$2.63
EPS
1.66
Beta
-
Dividend rate
Price and volume
Market cap
$1.2B
Beta
1.66
Financial strength
Current ratio
20.733
Quick ratio
20.181
Long term debt to equity
6.324
Total debt to equity
7.014
Management effectiveness
Return on assets (TTM)
-24.58%
Return on equity (TTM)
-40.40%
Valuation
Price to revenue (TTM)
32.047
Price to book
1.6
Price to tangible book (TTM)
1.61
Price to free cash flow (TTM)
-3.938
Growth
Revenue change (TTM)
2,873.65%
Earnings per share change (TTM)
-5.74%
3-year revenue growth (CAGR)
-24.96%
3-year earnings per share growth (CAGR)
-11.96%
What the Analysts think about RLAY
Analyst Ratings
Majority rating from 12 analysts.
RLAY Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$10M
-60.78%
Net income
-$81M
-76.22%
Profit margin
-813.00%
-39.36%
RLAY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.81
-$0.54
-$0.67
-$0.62
-
Expected
-$0.82
-$0.83
-$0.73
-$0.70
-$0.73
Surprise
-0.69%
-35.00%
-8.01%
-12.05%
-
RLAY News
AllArticlesVideos
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
GlobeNewsWire·2 months ago
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
GlobeNewsWire·2 months ago
Relay Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Relay Therapeutics stock?
Relay Therapeutics (RLAY) has a market cap of $1.2B as of July 27, 2024.
What is the P/E ratio for Relay Therapeutics stock?
The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of July 27, 2024.
Does Relay Therapeutics stock pay dividends?
No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Relay Therapeutics dividend payment date?
Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.
What is the beta indicator for Relay Therapeutics?
Relay Therapeutics (RLAY) has a beta rating of 1.66. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Relay Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.